Methods for manipulating satiety

• US 8,562,952 B2
• Filed: 03/01/2013
• Issued: 10/22/2013
• Est. Priority Date: 08/11/1999
• Status: Expired due to Fees

• Current Assignee: Cedars-Sinai Medical Center (Cedars Sinai Health System)
• Original Assignee: Cedars-Sinai Medical Center (Cedars Sinai Health System)
• Inventors: Lin, Henry C.
• Primary Examiner(s): Swartz, Rodney P.
• Application Number:
  US13/782,504
• Publication Number:
  US 20130177647A1
• Time in Patent Office: 235 Days
• Field of Search: 424/9.1, 424/9.2, 424/116, 424/278.1, 424/439, 426/5, 426/71, 426/658, 426/800, 426/801, 435/4, 435/29
• US Class Current: 424/9.2
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61B 5/0836 Measuring rate of CO2 production
• CPC Class Codes: A61B 5/412 Detecting or monitoring sepsis
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/201 having one or two double bonds, e.g. oleic, linoleic acids
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/4184 condensed with carbocyclic rings, e.g. benzimidazoles
• CPC Class Codes: A61K 31/424 condensed with heterocyclic ring systems, e.g. clavulanic acid
• CPC Class Codes: A61K 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 31/7036 having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• CPC Class Codes: A61K 31/7048 : having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/534 : Mentha (mint)
• CPC Class Codes: A61K 38/1796 : for hormones for neuromediators A61K38/1787
• CPC Class Codes: A61K 38/22 : Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/225 : Calcitonin gene related peptide
• CPC Class Codes: A61K 38/2271 : Neuropeptide Y
• CPC Class Codes: A61K 38/54 : Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 49/0004 : Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61K 51/1206 : Administration of radioactive gases, aerosols or breath tests
• CPC Class Codes: A61K 9/0053 : Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0087 : Galenical forms not covered by A61K9/02 - A61K9/7023
• CPC Class Codes: A61P 3/02 : Nutrients, e.g. vitamins, minerals
• CPC Class Codes: G01N 2033/4977 : metabolic gass from microbes, cell cultures, plant tissues and the like
• CPC Class Codes: G01N 2333/70571 : for neuromediators, e.g. serotonin receptor, dopamine receptor
• CPC Class Codes: G01N 2800/06 : Gastro-intestinal diseases
• CPC Class Codes: G01N 33/497 : of gaseous biological material, e.g. breath
• CPC Class Codes: G01N 33/6893 : related to diseases not provided for elsewhere
• CPC Class Codes: Y10S 426/80 : Geriatric
• CPC Class Codes: Y10S 426/801 : Pediatric
• CPC Class Codes: Y10T 436/145555 : Hetero-N
• CPC Class Codes: Y10T 436/147777 : Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
• CPC Class Codes: Y10T 436/18 : Sulfur containing
• CPC Class Codes: Y10T 436/214 : Acyclic [e.g., methane, octane, isoparaffin, etc.]
• CPC Class Codes: Y10T 436/22 : Hydrogen, per se

Abstract

Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal.

Claims

1. A method of weight management in a mammal in need thereof, comprising:

providing a composition comprising a serotonin receptor agonist, and a pharmaceutically acceptable carrier or an excipient; and

administering the composition to the mammal, whereby weight loss is induced in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron.

2. The method of claim 1, wherein administering is via oral delivery.

3. The method of claim 1, wherein administering is via enteral delivery.

4. The method of claim 1, wherein the mammal is human.

5. The method of claim 1, wherein the mammal is obese.

6. The method of claim 1, wherein the mammal is an obese human.

7. The method of claim 1, wherein the composition is in a coated tablet.

8. A method of inducing satiety in a mammal in need thereof, comprising:

providing a composition comprising a serotonin receptor agonist, and a pharmaceutically acceptable carrier or an excipient; and

administering the composition to the mammal, whereby a state of satiety is induced in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron.

9. The method of claim 8, wherein administering is via oral delivery.

10. The method of claim 8, wherein administering is via enteral delivery.

11. The method of claim 8, wherein the mammal is human.

12. The method of claim 8, wherein the mammal is obese.

13. The method of claim 8, wherein the mammal is an obese human.

14. The method of claim 8, wherein the composition is in a coated tablet.

15. A method of suppressing appetite in a mammal in need thereof, comprising:

providing a serotonin receptor agonist; and

administering the serotonin receptor agonist to the mammal, whereby the appetite is suppressed in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron.

16. The method of claim 15, wherein administering is via oral delivery.

17. The method of claim 15, wherein administering is via enteral delivery.

18. The method of claim 15, wherein the mammal is an obese mammal.

19. The method of claim 15, wherein the mammal is human.

20. The method of claim 15, wherein the mammal is an obese human.

21. The method of claim 15, wherein the composition is in a coated tablet.

22. A method of treating obesity in a mammal in need thereof, comprising:

providing a serotonin receptor agonist; and

administering the serotonin receptor agonist to the mammal, whereby obesity is treated in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron.

23. The method of claim 22, wherein administering is via oral delivery.

24. The method of claim 22, wherein administering is via enteral delivery.

25. The method of claim 22, wherein the mammal is human.

26. The method of claim 22, wherein the composition is in a coated tablet.